NextPharma upgrades sterile vial area at Belgian facility

NextPharma invests €2.4m on sterile vial area (SVA) at Braine-l'Alleud.

NextPharma has invested Euro 2.4m on upgrading its Sterile Vial Area (SVA) in Braine-l'Alleud, near Brussels.

The SVA for solution and lyophilised vials will complement existing sterile capabilities at the Belgian plant, covering ampoules, eye drops and cytostatics in vials. It should be operational by the end of the year.

NextPharma will be able to provide an integrated solution for non cytotoxic products, from development in the Braine l'Alleud Sterile Product Development Centre (SPDC) or at the firm's San Diego, US development centre, to commercial production scale up at Braine-l'Alleud.

"NextPharma's strategy for its Braine-l'Alleud facility has been to develop it as a centre of excellence for sterile development and manufacturing (both cytostatic and non-cytostatic, including biologics). The recent completion of the SPDC, our rapidly growing development centre in San Diego and now the SVA represent a key element of this strategy," said Hermann Osterwald, managing director of NextPharma Technologies, Contract Manufacturing Services.

NextPharma has initiated a programme for the implementation of FDA status at Braine l'Alleud, including extensive expansion and upgrading of its cytotoxics production capacity and capabilities. Additionally, it will develop new delivery dosage forms.

The company develops, manufactures, packages and distributes a range of products and formulations for its customers including solids, liquids and semi-solid dosage forms, antibiotics, hormones and controlled release medicines. The firm claims to be a leader in injectables manufacturing (lyophilised and liquid fill), with particular expertise in product development and manufacture of oncology medicines.

NextPharma has also been approved as a contract research organisation (CRO) by the French Ministry of Research (Ministere de l'Enseignement Superieur et de la Recherche) and will carry out r&d activities for French companies at its Sterile Product Development Centre. Companies subject to corporate tax in France will now be able to claim tax credits (Credit d'Impot sur la Recherche) for work subcontracted to NextPharma.



Companies